Ferring Receives U.S. FDA Approval for REBYOTA™ – A Novel First-in-Class Microbiota-Based Live Biotherapeutic
Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTAâ„¢ (fecal microbiota, live-jslm).
Ferring Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approved REBYOTAâ„¢ (fecal microbiota, live-jslm).
New research is revealing that cancer is rife with bacteria and fungi — a rich ecosystem that scientists call the tumor microbiome.
Cancer-microbe associations have been explored for centuries, but cancer-associated fungi have rarely been examined.
Our growing awareness of the microbial world’s importance and diversity contrasts starkly with our limited understanding of its fundamental structure.
Due to its fundamental role in the induction, training, and function of the immune system, it is critical to include characterizations of the gut microbiome in clinical trials and studies that aim to broaden our understanding of coronavirus disease 2019 (COVID-19).
Environmental factors, mucosal permeability and defective immunoregulation drive over- active immunity to a subset of resident intestinal bacteria that mediate multiple inflammatory conditions.
The Microbiome as a source of new enterprises and job creation: Considering clinical faecal and synthetic microbiome transplants and therapeutic regulation.